“In-Vitro Diagnostics market set to grow to $84bn by 2022” says new Visiongain report

11 September 2018
Pharma

Visiongain has launched a new pharma report: In-Vitro Diagnostics World Market 2018-2028: Point of Care, Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Molecular Diagnostics, Flow Cytometry, Infectious Diseases, Diabetes, Cardiology, Autoimmune Diseases, Renal Diseases, Pharmacogenomics, HIV/AIDS, Reagent & Kits, Instruments, Data Management Software & Services, Hospitals, Laboratories, Home Care Testing, Research Institutes, Blood Glucose Testing, Infectious Disease Testing, Rapid Coagulation Testing, Cholesterol Testing, Pregnancy Testing, Basic Metabolic Panel, Electrolyte Panel, Liver Profile, Lipid Profile, Thyroid Function Test, ELISA, Immuno-PCR, Rapid Test, Western Blot, Enzyme linked Immunospot Assay

In vitro diagnostic (IVD) tests are medical assays performed on bodily fluids or tissues, as a diagnostic tool for a range of clinical disorders. The information obtained from such tests may act as a key factor in the decision making of a patient’s particular treatment plan. Examples of tests currently performed today include measuring the concentrations of various chemical and biochemical components, counting cells, measuring physical properties of the sample, microscopic examination of cells and other structures or preparing biological cultures. The generally positive outlook for the IVD industry has led to a large amount of merger and acquisition activity over previous years. These market trends are set to continue as the larger industry leaders look to consolidate power in an industry which is set to be worth $78.4bn by 2020.

The lead analyst of the report commented "Strengths in the IVD market primarily results from patient demographics. The rise in the global aging population will bear witness to an increasing incidence of age-related diseases, such as cardiovascular disease and cancer. This in turn has fuelled demand for advanced diagnostic testing equipment, capable of providing accurate clinical diagnoses, which allows for earlier medical intervention.

In addition, technological innovations in this field have introduced increasingly miniaturised and automated devices into the marketplace, which has given rise to a new range of condition-specific tests. Furthermore, continued research and development in IVD has allowed the discovery of new biomarkers, which has expanded the clinical application of IVD testing."

Leading companies featured in the report include Abbott Diagnostics, Agilent Technologies, Becton, Dickinson and Company (BD), BioMerieux, Bio-Rad, Danaher Corporation, DiaSorin Diagnostics s.p.a, Roche Diagnostics, Siemens Diagnostics, Sysmex Corporation

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Influenza Vaccines Market Report 2020-2030

For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.

30 September 2020

Read

Visiongain Publishes Next-Generation Pharmaceutical Temperature Management Solutions Market Report 2020-2030

Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.

28 September 2020

Read

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2020-2030

The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.

23 September 2020

Read

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever